Related Experiment Videos
Cellular immunity in cancer patients against embryonal cells
Journal of the National Cancer Institute
|August 1, 1973
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Bio-Inspired lipid nanovesicles (iNVs) incorporating membrane proteins from healthy tendon stem cells for targeted protein restoration in tendinopathic in vitro model.
Artificial cells, nanomedicine, and biotechnology·2026
Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis.
Multiple sclerosis and related disorders·2022
Myogenic commitment of human stem cells by myoblasts Co-culture: a static vs. a dynamic approach.
Artificial cells, nanomedicine, and biotechnology·2022
Refining risk stratification of patients with early breast cancer eligible for adjuvant abemaciclib or ribociclib.
Journal of the National Cancer Institute·2026
Somatic alterations in TP53, PIK3CA, and CCND1 reveal exposure-driven patterns in oral and oropharyngeal tumors.
Journal of the National Cancer Institute·2026
Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan.
Journal of the National Cancer Institute·2026
Examining the role of extrachromosomal DNA in lung cancer.
Journal of the National Cancer Institute·2026
Differential impact of lymphocytes on radiation response in autochthonous vs transplant murine sarcomas.
Journal of the National Cancer Institute·2026
Nitrate and nitrite intake and risk of colorectal cancer: a population-based cohort study.
Journal of the National Cancer Institute·2026
Development of cecal volvulus after redo pancreas transplantation.
Journal of surgical case reports·2026
Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.
Iranian journal of otorhinolaryngology·2026
Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.
Research and practice in thrombosis and haemostasis·2026